Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Summit Therapeutics Inc (NASDAQ: SMMT) was $16.81 for the day, down -1.35% from the previous closing price of $17.04. In other words, the price has decreased by -$1.35 from its previous closing price. On the day, 4.08 million shares were traded. SMMT stock price reached its highest trading level at $17.16 during the session, while it also had its lowest trading level at $16.27.
Ratios:
Our analysis of SMMT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 17, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $13.Barclays initiated its Underweight rating on September 17, 2025, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 12514078720 and an Enterprise Value of 12280952832.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.45, which has changed by -0.06373626 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -5.80%, while the 200-Day Moving Average is calculated to be -22.79%.
Shares Statistics:
SMMT traded an average of 2.92M shares per day over the past three months and 2872120 shares per day over the past ten days. A total of 744.44M shares are outstanding, with a floating share count of 102.73M. Insiders hold about 86.17% of the company’s shares, while institutions hold 14.08% stake in the company. Shares short for SMMT as of 1767139200 were 37009569 with a Short Ratio of 12.67, compared to 1764288000 on 32347593. Therefore, it implies a Short% of Shares Outstanding of 37009569 and a Short% of Float of 31.25.
Earnings Estimates
Currently, 11.0 analysts are dedicated to thoroughly evaluating and rating the performance of Summit Therapeutics Inc (SMMT) in the stock market.The consensus estimate for the next quarter is -$0.08, with high estimates of $0.71 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.1 and -$1.1 for the fiscal current year, implying an average EPS of -$0.76. EPS for the following year is -$0.74, with 10.0 analysts recommending between -$0.43 and -$1.18.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $1.89M in the next fiscal year. The high estimate is $44.12M and the low estimate is -$62.12M.
